# A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

> **NCT02492789** · PHASE1 · COMPLETED · sponsor: **Atridia Pty Ltd.** · enrollment: 49 (estimated)

## Conditions studied

- Solid Tumors and Hematologic Malignancy

## Interventions

- **BIOLOGICAL:** INCSHR01210 injection

## Key facts

- **NCT ID:** NCT02492789
- **Lead sponsor:** Atridia Pty Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-01
- **Primary completion:** 2019-03-01
- **Final completion:** 2019-07-05
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2019-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02492789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02492789, "A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02492789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*